Menu
Back to Journals » Clinical Pharmacology: Advances and Applications » Volume 5 » Issue 1
Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX® mesalamine. [Corrigendum]
Received 7 January 2013
Accepted for publication 7 January 2013
Published 22 January 2013 Volume 2013:5(1) Pages 21—22
Nanda K, Moss AC.Clinical Pharmacology: Advances and Applications. 2012, 4:41–50.
The authors apologize for errors on Tables 1, 2, and 3.
Table1
Citation 40, Hussain et al, should have been citation 44, Shire US Inc.
Table 2
Lichtenstein et al data, the confidence interval (CI) of the odds ratio for achieving remission with MMX mesalamine 1.2 g twice daily (1.44–8.41) should be listed as a 97.5% CI rather than a 95% CI.
Table 3
Prantera et al, the MMX mesalamine 2.4 g once daily cohort should have an N value of 156, not 162, and the 12-month relapse rate should be 25.0%, not 15.0%.
Pramtera et al, the Asacol 2.4 g once daily cohort should be labeled "Asacol 2.4 g/day twice daily", and should have an N value of 167, not 156.
Kane et al, the N value should be 194, not 167.
Read the original article
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.